ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 9.01 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b)On November30, 2017, Scott J. Charles, the Company’s Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer) resigned from his position with Aralez Pharmaceuticals Inc. (the “Company”), effective immediately.

(c)On November30, 2017, the Company promoted Michael Kaseta, 42, as the Company’s Head of Finance and Interim Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer), effective November30, 2017. Mr.Kaseta has served as the Company’s Corporate Controller since September26, 2016. Prior to joining the Company, Mr.Kaseta held various positions at Sanofi S.A. (“Sanofi”), including most recently Chief Financial Officer Sanofi North America, Global Services, from April2015 through September2016. Mr.Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January2013 through April2015, Vice President, Sanofi Financial Shared Services from March2007 through December2013 and Director of Technical Accounting from 2005 to 2007.

(e)The material economic terms of Mr.Kaseta’s compensation as Head of Finance and Interim Chief Financial Officer (Principal Financial Officer, Principal Accounting Officer) are summarized below:

Annual Base Salary: Mr.Kaseta will receive an annual base salary of $350,000.

Target Bonus: Mr.Kaseta will be eligible for an annual performance-based incentive bonus with a target bonus opportunity equal to 35% of his annual base salary, provided that Mr.Kaseta remains employed by the Company.

Promotion Equity Award: In connection with his promotion, Mr.Kaseta was awarded 25,000 options to purchase shares of the Company’s common stock to the Company’s Amended and Restated 2016 Long-Term Incentive Plan.

A copy of the Company’s press release announcing these matters is attached hereto as Exhibit99.1 and the information contained therein is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d)List of Exhibits


Aralez Pharmaceuticals Inc. Exhibit
EX-99.1 2 a17-27804_1ex99d1.htm EX-99.1 Exhibit 99.1     ARALEZ ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER   Mississauga,…
To view the full exhibit click here

About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).